about
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGDEnhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive LiposomesA small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.Recent developments in antiangiogenic therapy.Tyrosine kinases as targets in cancer therapy - successes and failures.(99m)Tc-3P-RGD2 molecular imaging targeting integrin α v β 3 in head and neck squamous cancer xenograftTargeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles.Positron emission tomography tracers for imaging angiogenesis.Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hopeAntibody-targeted liposomes in cancer therapy and imaging.Cytotoxicity, anti-angiogenic, apoptotic effects and transcript profiling of a naturally occurring naphthyl butenone, guieranone A.Antiangiogenics and radiotherapy.Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.SPIO-RGD nanoparticles as a molecular targeting probe for imaging tumor angiogenesis using synchrotron radiation.Cloning and expression of human vascular endothelial growth factor gene and inhibition of its expression by antisense in prokaryotic system.Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways.A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo.Multimodality Imaging in Tumor Angiogenesis: Present Status and PerspectivesBinding affinities for sulfonamide inhibitors with matrix metalloproteinase-2 using a linear response method.Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice.Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
P2860
Q24805375-95492D40-3416-41C0-8CE2-8F2649EB67B4Q27314854-59C0C046-7F96-4399-B72D-55519690C70CQ34099015-09064821-9D18-431F-B6CB-6643EB49E16BQ35040867-EFAF238B-3C8E-47D7-84D6-8B25785E7E31Q35095147-47644F9C-CF3E-4DD8-AD74-6DE7C6EA2A34Q35888323-B62EA4F0-8222-4983-BBE6-4E8DC6E68620Q36395067-2228CF7B-DB7A-4D71-B937-DC5C7D230911Q36777285-06D67D3F-53EC-46E6-9106-BEA0480066E0Q36884230-0A7A0DBD-933E-4CDD-9331-E5B6D4CE6C1EQ37076367-68D688E4-57AC-4437-BD90-9930283C14E9Q37196745-71E2EE44-06CC-4D66-927F-1F827C6B8CC4Q37222791-E02CD585-A290-4CCB-986F-01B574A1D11EQ39456618-25931F81-DB89-4B74-A9F4-B43A8757E0E1Q39521937-A53C1058-B45A-4728-B8AE-EFB4E7459FC9Q39757470-D871447B-CECE-47C1-B0AF-8E57659957FCQ40432060-36C683A2-855C-4E56-A459-629C351E4FDAQ40538646-208401AF-C61D-4CCE-BDBB-DA1BBDED9BDEQ41661199-2C8B461B-B02C-4FDA-B2E4-BBE5C8865219Q42642728-618AF9D1-ECDF-4F68-8234-7B612554CB9FQ45174628-0B0EA92C-6677-43B8-9C88-5D52A9023CDEQ49441016-6F55BEDD-1D3C-426E-91B2-AA67ED284094
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tumor angiogenesis as a therapeutic target.
@ast
Tumor angiogenesis as a therapeutic target.
@en
Tumor angiogenesis as a therapeutic target.
@nl
type
label
Tumor angiogenesis as a therapeutic target.
@ast
Tumor angiogenesis as a therapeutic target.
@en
Tumor angiogenesis as a therapeutic target.
@nl
prefLabel
Tumor angiogenesis as a therapeutic target.
@ast
Tumor angiogenesis as a therapeutic target.
@en
Tumor angiogenesis as a therapeutic target.
@nl
P1433
P1476
Tumor angiogenesis as a therapeutic target.
@en
P2093
P304
P356
10.1016/S1359-6446(01)01939-0
P577
2001-10-01T00:00:00Z